# Alder Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alder-therapeutics

- Industry: Biotechnology
- Headquarters: Stockholm, Sweden
- Website: www.aldertx.com
- Total disclosed funding: $1.8M
- Latest round: Seed (Sep 26, 2022)
- Investors on record: 2

## About

Based in Stockholm, Sweden, and founded in 2022, Alder Therapeutics AB operates as a biotechnology company specializing in cell therapy. In September 2022, the firm raised SEK 20 million in seed funding co-led by investors Flerie Invest and Linc AB. The firm as of July 2023, is led by its CEO, Kristian Tryggvason.

The company specializes in cell therapy with a focus on manufacturing retinal and cardiac cell therapeutic products. The company’s flagship solution is Alder Edge, a technology that enhances the differentiation process of pluripotent stem cells, ensuring greater reproducibility and robustness in cell manufacturing. By utilizing the Alder Edge, customers can expect more homogeneous and quality cell therapy products every single time.

The company plans to utilize its September 2022 funding to further develop its product offerings with a focus on enhancing differentiation protocols and advancing clinical and regulatory strategies and growing its workforce.

## Funding rounds

- Seed, Sep 26, 2022, $1.8M — Flerie Invest, Linc AB

## Investors

- Flerie Invest (https://capitalatlas.ai/funds/flerie-invest) — Seed
- Linc AB — Seed